SLC5A2 and type 2 diabetes mellitus: Does the efficacy of sodium-glucose cotransporter 2 inhibitors, glucagon-like peptide-1 receptor agonists, and dipeptidyl peptidase 4 inhibitors vary by age and sex among individuals with type 2 diabetes?